Login to Your Account



AVEO Signs Potential $477M Schering-Plough Collaboration

By Jennifer Boggs


Thursday, April 5, 2007
Cancer drug company AVEO Pharmaceuticals Inc. is partnering a preclinical antibody program with Schering-Plough Corp. for worldwide development and commercialization in a deal that could be worth up to $477.5 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription